S-1/A: Kairos Pharma Eyes NYSE American Listing with $6.2 Million IPO

Kairos Pharma, a clinical-stage biopharmaceutical company, is seeking to raise $6.2 million through an initial public offering to advance its cancer therapeutics pipeline.

Summary

• Kairos Pharma, a clinical-stage biopharmaceutical company, is planning an initial public offering of 1,550,000 shares of common stock, expecting the initial public offering price will be $4.00 per share.
• The company aims to list its common stock on the NYSE American under the symbol KAPA.
• Kairos Pharma intends to use the net proceeds of approximately $5.6 million to fund Phase 1 and Phase 2 clinical trials of its product candidates, including ENV 105 and preclinical product candidates including KROS 101, potential acquisition or in-licensing activities, and for working capital and general corporate purposes.
• The company's pipeline includes seven drug candidates targeting various cancers, including prostate, lung, breast cancer and glioblastoma.
• ENV 105, an antibody targeting CD105/Endoglin, is currently in Phase 2 trials for prostate cancer and Phase 1 trials for lung cancer, with patient enrollment beginning in September 2023.
• The company has licensed key patents from Cedars-Sinai Medical Center and Tracon Pharmaceuticals, Inc.
• The company received notification on May 21, 2024, that the NIH was awarding a grant of $3.3 million to support the development of the mechanism of action and companion biomarkers for the ongoing Phase 2 trial for ENV105.
• The company has identified material weaknesses in its internal control over financial reporting and is taking steps to remediate them.

Sentiment

Score: 5

Explanation: The document presents a balanced view, highlighting both the potential of the company's pipeline and the risks associated with its early stage of development and financial position. The inclusion of a going concern explanatory paragraph tempers the overall sentiment.

Positives

• The company has a diversified pipeline of seven drug candidates.
• ENV 105 has shown a clinical benefit rate of 62% in an investigator-initiated Phase 2 trial for prostate cancer.
• The company has secured key licensing agreements with Cedars-Sinai Medical Center and Tracon Pharmaceuticals, Inc.
• The company received notification on May 21, 2024, that the NIH was awarding a grant of $3.3 million to support the development of the mechanism of action and companion biomarkers for the ongoing Phase 2 trial for ENV105.

Negatives

• The company has a limited operating history and has incurred significant losses since its inception.
• The company will need to obtain substantial additional funding to meet its financial needs and pursue its business objectives.
• The company has identified material weaknesses in its internal control over financial reporting.
• The report of the company's independent registered public accounting firm included a going concern explanatory paragraph.

Risks

• The company requires substantial additional funding to meet its financial needs and to pursue its business objectives.
• The company faces substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than the company does.
• The company is relying exclusively on the skills and expertise of its management team in conducting its business, not all of whom will devote all of their time to managing the Company, and the company currently has no full-time employees, which may impede its ability to carry on its business.
• The company's exclusive licensing rights to its intellectual property are subject to agreements with third parties and the company may not meet milestones set forth in those agreements or its exclusive licensing rights may be terminated.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if the company is ultimately unable to obtain regulatory approval for its product candidates, its business will be materially harmed.
• The trading price of the company's common stock may be volatile, and you could lose all or part of your investment.

Future Outlook

The company expects to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as it advances its product candidates through clinical development, seeks regulatory approval, and operates as a public company.

Industry Context

The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. The immuno-oncology segment of the industry is in particular highly competitive.

Comparison to Industry Standards

• The document mentions competitors such as Pfizer and AstraZeneca, but does not provide a detailed comparison of Kairos Pharma's results to industry standards.
• The document mentions that the global prostate cancer therapeutics market size was valued at USD 7.9 billion and at USD 1.7 billion for EGFR mutant non-small cell lung cancer, but does not provide a detailed comparison of Kairos Pharma's results to industry standards.

Related Party Transactions

• Two officers and shareholders agreed to convert the $0.004 million due to them into 1,664 shares of the Companys common stock, effective upon the closing of the Companys IPO.
• Subsequent to December 31, 2023, the Company borrowed $72 from three of its officers. The loans accrue interest at 7.5%, are due in April 2025 and are unsecured.
• On May 22, 2024, the Company borrowed $30 from two of its officers. The loans accrue interest at 7.5%, are due in May 2025 and are unsecured.

Stakeholder Impact

• Shareholders will experience dilution as a result of the IPO.
• The company's success will depend on its ability to attract, retain, and motivate qualified personnel.
• The company's product candidates may offer new treatment options for cancer patients.
• The company's relationships with key stakeholders, such as healthcare professionals and third-party payors, will be subject to applicable healthcare laws and regulations.

Next Steps

• Complete Phase 1 and Phase 2 clinical trials of ENV 105.
• Complete pre-IND studies for the checkpoint inhibitor KROS 101.
• Initiate a Phase 1 trial of activated T cell therapy for KROS 201 in patients with glioblastoma.
• Continue to advance the pipeline of immunotherapeutics for clinical trials.
• Seek regulatory approvals for product candidates.
• Establish sales, marketing, and distribution capabilities or enter into agreements with third parties to commercialize product candidates.

Key Dates

Keywords

Kairos Pharma, IPO, biopharmaceutical, cancer therapeutics, ENV 105, KROS 101, clinical trials, drug development, NYSE American, oncology, immunotherapy